top of page
Ecosystem
Beta Site
Search Results
3 items found for "ChemoCentryx"
- Amgen to Acquire Chemocentryx for $4 Billion in Cash
., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx , Inc., (NASDAQ: CCXI), a biopharmaceutical announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx
- ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated ...
January 2022 ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated
- Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European ...
. , Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx , Inc. , (Nasdaq: CCXI), today announced that the
bottom of page